HK Stock Market Move | BOAN BIOTECH (06955) rose more than 14%. The company currently has sufficient cash reserves and institutions are optimistic about its potential in the FIC innovation pipeline market.

BOAN BIOTECH (06955) rose more than 14%, as of the time of publication, it rose by 10.46% to 14.36 Hong Kong dollars, with a turnover of 2.9 billion Hong Kong dollars. Huaan pointed out that in the first half of the year, BOAN BIOTECH controlled expenses reasonably, the launch of the new product Dorirabtinib led to a temporary decrease in gross profit margin, the research and development expense ratio decreased dynamically in the short term, and the sales expense ratio fluctuated reasonably. The company currently has sufficient cash to support the rapid advancement of the innovative drug pipeline. In addition, BOAN BIOTECH has built four major technology platforms based on years of experience in molecular discovery, clinical development, and production quality control of large molecules. These platforms include the whole human antibody transgenic mouse platform, the bispecific TCE technology platform, the ADC technology platform, and the AI application platform, laying out the new generation IO+ADC therapy. The company's BA-huMab whole human antibody transgenic mouse platform, which includes 30 human antibody light chain variable region genes and 110 human antibody heavy chain variable region genes (IgM and IgG1), can rapidly induce an immune response and generate high antibody titers after immunization. It has been validated in numerous antibody projects. On the ADC platform, the company continues to upgrade with differentiated toxins and indications for CLDN18.2 ADC, differentiated targets for CD228 ADC, and the next generation bispecific ADC, as well as bispecific toxin ADC. Huaan is optimistic about the company's full-chain capability in the biopharmaceutical platform and the large market potential of the FIC innovation pipeline.